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Inhalation is the preferred route of drug administration in chronic respiratory diseases because it opti-
mises delivery of the active compounds to the targeted site and minimises side effects from systemic
distribution. The choice of a device should be made after careful evaluation of the patient's clinical
condition (degree of airway obstruction, comorbidities), as well as their ability to coordinate the inha-
lation manoeuvre and to generate sufﬁcient inspiratory ﬂow. These patient factors must be aligned with
the speciﬁc advantages and limitations of each inhaler when making this important choice. Finally,
adherence to treatment is not the responsibility of the patient alone, but should be shared also by cli-
nicians. Clinicians have access to a wide selection of pressurised metered dose inhalers (pMDIs) and dry
powder inhalers (DPIs) that can be used effectively when matched to the needs of individual patients;
this should be perceived as an opportunity rather than a limitation.
© 2015 Elsevier Ltd. All rights reserved.1. Introduction
Chronic diseases require regular treatment. This applies to
asthma and chronic obstructive pulmonary disease (COPD), the
most common chronic respiratory conditions, which are charac-
terised by persistent airway inﬂammation and bronchial obstruc-
tion. Inhalation is the preferred route of administration when
treating respiratory obstructive diseases, because it optimises the
delivery of active compounds to the targeted site, while minimising
side effects. In this context, the inhaler plays a crucial role in the
management of chronic respiratory diseases. The choice of the
device can be as important as the choice of the drug. In real-life
clinical settings, physicians often discuss on the properties of
various drugs with their colleagues and patients, in order to agreeina e Medicina Specialistica
0146 Palermo, Italy. Tel.: þ39
hilone).on the best possible choice for the patient, whereas little consid-
eration is given to the properties of different inhalers. We believe
that priority should be given to the choice of the appropriate de-
vice, based on patient needs and expectations, followed by the
choice of the drug, based on the disease and its severity. A
consensus statement by the task force of the European Respiratory
Society (ERS) and the International Society for Aerosols in Medicine
(ISAM) provides clear recommendations for choosing the best
aerosol delivery device based on a patient's actuationeinhalation
coordination, level of inspiratory ﬂow, and other clinical conditions
[1]. For example, some inhalers require strong inspiratory force,
which may not be possible in emergency situations or in children
and elderly.
Ideally, patients should use one device for all of their inhaled
therapies; obviously, this is not always possible. We believe that
differences in efﬁcacy among devices become trivial in case of
correct inhalation technique, as supported by evidence-based
guidelines from the American College of Chest Physicians/Amer-
ican College of Asthma, Allergy, and Immunology [2]. The key issue
is patient training and veriﬁcation of the inhalation technique. The
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with each device. The current review article aims at comparing the
available inhaler devices to assess their advantages and limitations
in chronic obstructive diseases. The role of the devices with regard
to adherence to treatment will be also addressed.
2. Role of the inhaler in the management of chronic
obstructive respiratory diseases
The goal of therapy is to obtain optimal control of symptoms
and, ideally, to alter the natural course of the disease by delivering
the correct drug dosage to the site of structural and functional al-
terations. To achieve this, two conditions must be met: 1) the
aerosol formulation must deposit along the bronchial tree, and 2)
drug deposition must provide functional and clinical beneﬁts. Both
conditions are closely related to the type of device used. Treatment
effectiveness is also determined by adherence to therapy. In this
context, adherence is inﬂuenced by many factors, and inhaler de-
vice preference could be one of them. Individuals suffering from
chronic respiratory diseases ask for a device that is simple to use,
easy to carry and to check, and accomplishing these conditions may
help to reduce some of the issues associated with the lack of
adherence. Taken together, these observations emphasize the
important role played by the inhalation device in clinical practice;
choosing the correct inhaler is the primary step for optimal control
of the disease.
3. Key points in managing treatment by inhaled medications
Despite the clinical importance of inhaled therapy, current
guidelines seem to lack a consensus on recommendations for de-
vices. Less than 3% of the ofﬁcial documents for management of
asthma and COPD focus on device-related issues. Guidelines are
generally vague and not always evidence-based regarding criteria
for choosing inhaler devices, especially for adults, thus allowing
clinically irrelevant factors to inﬂuence the choice.
Looking at a pressurised metered dose inhaler (pMDI), for
instance, the deposition pattern of the inhaled drug is the result of a
complex interaction between the device, the aerosol formulation
and the patient's inhalation technique. When an aerosol is inhaled,
the drug is deposited at the target site, the bronchi, and also
unavoidably in themouth. A variety of inhalation devices have been
introduced in clinical practice over time, differing in terms of
design (required inspiratory ﬂow rate, actuation), composition
(propellant characteristics, carrier substances), dose per inhalation
and cost.
Deposition in the bronchial tree occurs through three different
modalities: a) inertial impaction, b) sedimentation, and c) diffusion.
Inertial impaction occurs when larger particles deposit in proximal
airways, where the velocity of airﬂow is highest. Sedimentation
occurs when suspended particles deposit through the force of
gravity; these suspended particles may be exhaled before they
deposit. The smallest particles are able to reach the distal parts of
the lung, where they contact the airway walls because of Brownian
motion. Thus, the choice of a device should be driven by the tar-
geted airway site. For example, devices that produce 3e5 mm
droplets are used to deliver antibiotics to the proximal airways [3];
on the other hand, smaller particles are needed to reach the distal
lung, where most functional and structural airway changes occur in
chronic obstructive diseases. Finally, the clinical beneﬁt provided
by inhaled therapy is inﬂuenced by patient factors, such as adher-
ence, particularly in paediatric and elderly patients. Adherence is
critical for the clinical outcomes, as well as correct technique, and
this has driven demand for more user-friendly devices. Treatment
effectiveness is strongly dependent on thewillingness and ability ofthe patient to perform the prescribed therapy, particularly for
chronic or long-term therapies. Training and practice are required
to improve delivery of the inhaled drug to the targeted site. Un-
fortunately, this aspect is often neglected in daily practice and can
negatively inﬂuence outcomes.
4. Drug deposition according to device selection
pMDIs are the most widely used devices. Their correct use re-
quires coordination between inhalation and device actuation.
Incorrect technique can limit the effectiveness in daily clinical
practice; lack of coordination can occur with pMDIs and represents
almost half of all errors [4]. This can lead to ineffective drug delivery
to the lungs with excess deposition in the oropharynx. To overcome
this limitation, the use of a spacer with pMDIs is often recom-
mended, especially for patients with known or suspected poor
coordination (e.g., children, elderly).
The pMDI canister is formulated as either a suspension or a
solution, which differ in terms of particle size, plume velocity and
duration. In suspension formulations, the active drug is not soluble
in the propellant and remains a solid powder in the container.
Consequently, the inhaler must be shaken to ensure uniform dis-
tribution of the particles and a constant emitted dose at each use.
Up to 25% of patients do not shake the device properly [5], which
results in a variable amount of emitted drug for each aerosol puff.
Moreover, suspension formulations require a larger oriﬁce to avoid
blockage, which in turn induces aerosol plumes of higher velocity
and lower duration. Transition from chloroﬂuorocarbon (CFC) to
hydroﬂuoroalkane (HFA) propellants has allowed a shift from sus-
pension to solution formulations, in which the drug is uniformly
distributed.
Breath-activated pMDI (BA-pMDI) devices are also available,
releasing drug when inhalation triggers the metered-dose inhaler,
avoiding any coordination issues. Currently, there is only one
commercially available soft mist inhaler: the Respimat, which at-
omises the drug solution using mechanical energy imparted by a
spring, producing a ﬁne, slow-moving mist, with less deposition in
the mouth and throat and relatively higher lung deposition [6]. The
Respimat inhaler was designed to aerosolize most of the metered
volume in the form of droplets with a diameter of >1 mm (to avoid
loss of small droplets during the subsequent exhalation) and
<5.8 mm (to facilitate efﬁcient lung deposition). The ﬁne particle
fraction (FPF) for the Respimat is approximately 75% with most
formulations. A second parameter that inﬂuences the deposition of
the drug is the velocity of the particles during inhalation; higher
velocities promote particle impaction in the throat. The spray
duration of the Respimat is approximately 1.2 s and is considerably
longer than for pMDIs (typically 0.15e0.36 s). The long duration of
the soft mist allows for better chances of coordinating the inhala-
tion manoeuvre with the drug release [6].
Soon after the introduction of pMDIs in the management of
respiratory diseases, dry powder inhalers (DPIs) were developed to
deliver therapy in patients with asthma or COPD. Three types of
DPIs are available with different handling instructions: single dose
(Breezhaler, HandiHaler, Aerolizer), multiple dose (Diskus) and
reservoir (Turbuhaler). The major advantage of DPIs is that they do
not require coordinated activation, because the drug is not driven
by a propellant but is delivered by the inhalation itself. Thus, DPI
devices like the Diskus and the Turbuhaler require higher inspira-
tory ﬂows than pMDIs to assure optimal drug delivery, because
both particle size and the amount of drug reaching the lower air-
ways depend on the peak inspiratory ﬂow [7]. In addition, whereas
all pMDIs employ the same inhalation technique, each DPI device
requires speciﬁc training, which may generate confusion among
patients, and may increase the risk of errors.
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The ﬁrst area to explore when comparing different inhaler de-
vices is the particle size range of the emitted dose. Aerosol particle/
droplet size is one of the most important factors inﬂuencing the
deposition of medications in the airways. A particle size of 2e5 mm
has the greatest potential to be deposited throughout the bronchial
tree. Indeed, smaller particles deposit into the alveoli, where there
is no smooth muscle and where systemic absorption is increased
[8]. Particles >5 mm tend to settle in the mouth and oesophageal
region, where they produce no clinical effect but can potentially
produce both local and systemic side effects after gastrointestinal
absorption [8]. Consequently, differences in particle size of the
aerosol emitted from inhalation devices may inﬂuence functional
and clinical responses. Aerosol particle size depends on drug-,
formulation- and device-related factors. Two parameters are used
to deﬁne the particle size: the mass median aerodynamic diameter
(MMAD), which is the droplet size at which half of the mass of the
aerosol is contained in smaller droplets and half in larger droplets,
and the ﬁne particle fraction (FPF), meaning the percentage of
particles <5 mm in diameter. Generally, FPF is proportional to the
fraction of emitted dose reaching the lung. However, it should be
noticed that these are extrapolations of in vitromeasurements, and
should be used with caution in humans. Indeed, lung deposition of
the drug depends on several factors that interact, such as the
inhalation ﬂow, the particle size and the drug formulation (Fig. 1).
Development of environment-friendly HFA propellants has led to
the production of extraﬁne formulations. The Modulite technology
has been developed to provide a slow moving cloud of particles
with a speciﬁc particle size. This was achieved by incorporating a
non-volatile component in the formulation and modifying the ge-
ometry of the actuator. Currently, there are several single-agent
extraﬁne formulations on the market (beclomethasone, cicleso-
nide, formoterol), and only one combination product available
(beclomethasone/formoterol) [1]. Extraﬁne solution pMDIs can
deliver compounds with a smaller MMAD than other available
devices [9]. It is important to note that non-extraﬁne combinations
are also capable of reaching the lung periphery: budesonide/for-
moterol delivered by a Turbuhaler signiﬁcantly improved small
airway impairment in asthma patients compared with ﬂuticasone/
salmeterol by Diskus [10]. However, peripheral deposition of
extraﬁne combinations is several fold higher compared with non-
extraﬁne combinations [11].
An in vitro study comparing the proportion of the nominal dose
of different corticosteroids delivered as ﬁne drug particles from
four different DPIs at different ﬂow rates showed that the Tur-
buhaler device produced a higher proportion of respirable particlesFig. 1. Description of factors affecting lung deposition of the inhaled drug.than the other devices, and this was consistent across the range of
applied inspiratory force [12]. These in vitro ﬁndings need to be
conﬁrmed with in vivo deposition studies.
Gamma scintigraphy of inhaled radiolabeled drugs shows that
the amount of drug deposited in the lungs is a function of the
inhalation technique, the inhaled product, or both. This in vivo
method revealed signiﬁcant differences between devices with
respect to pulmonary deposition, with values ranging from
approximately 5% to over 50% for currently available pMDIs and
DPIs. However, the relationship between the drug particle size, the
deposition of the drug and the clinical and functional beneﬁt is not
straightforward. In particular, it is still unknown what is the
optimal particle size able to provide greater improvements in lung
function. In this regard, the discrepancy between the study from
Zanen et al. [13] and that from Usmani et al. [14] which speciﬁcally
addressed the clinical beneﬁt as a function of the particle size of the
inhaled bronchodilator, could be only apparent, since the asthmatic
volunteers differed in terms of magnitude of airway obstruction.
Findings with this methodology generally replicate those obtained
with the Andersen impactor device. Regarding DPIs, Turbuhaler
delivers approximately 25e35% of the labelled dose to the lung,
whereas the Diskus delivers about half this amount [15]. The lung
deposition from Turbuhaler is signiﬁcantly greater than from a
pMDI [16]. The two-fold improvement in pulmonary deposition
with Turbuhaler, compared with Diskus, is consistent with in vitro
particle assessment using an Andersen impactor. However, as
already mentioned the in vitro ﬁndings can be poor predictors of
in vivo conditions. The differences in lung deposition may be due to
the larger amount of ﬁne particles generated by Turbuhaler,
compared with Diskus or the pMDIs, due to disaggregation of the
agglomerated formulation in the spiral channels of Turbuhaler.
Diskus has coarse particles combined with a lactose carrier that has
limited capacity for generating ﬁne particles [17]. Lung deposition
is more consistent with Turbuhaler thanwith Diskus (coefﬁcient of
variation 20% vs. 40%) [15,18]. Other inhalers, such as NEXThaler,
have demonstrated good performance despite the degree of bron-
chococonstriction and underlying disease. In healthy volunteers,
55% of the labelled dose was delivered, compared with 56% in pa-
tients with asthma and 55% in patients with COPD [19]. Breezhaler
was studied by Choltorpe and colleagues [20], showing that the
medium ﬁne particles fraction was 42.6% of the labelled dose, with
a MMAD of 2.8 mm for glycopyrronium. The intrathoracic deposi-
tion was of 39% for glycopyrronium while extrathoracic deposition
was about 45% [20].
Whereas these physical and mechanical characteristics per se do
not imply a clinical advantage, it is logical to assume that the
clinical beneﬁt is related to the fraction and variability of lung
deposition of the active drug. The inspiratory ﬂow must also be
considered, because inhaler efﬁciency is strongly dependent on the
production of an adequate peak inspiratory ﬂow. Each inhaler has a
minimum energy (i.e., inhalation ﬂow) required to provide efﬁcient
disaggregation of the formulation. In the study by Tarsin [7], both
Diskus and Turbuhaler seem to require high inspiratory ﬂows to
assure optimal drug delivery, and there is a more signiﬁcant effect
of inspiratory ﬂow on variable dosage emission when using the
Turbuhaler compared with the Diskus. Whereas minimum inha-
lation ﬂows are not clearly deﬁned for each device, they are
important because of the potential risk for a patient to receive a
non-appropriate dose. In general, very young and elderly patients,
and those experiencing a severe exacerbation may not be able to
generate sufﬁcient inhalation ﬂow to generate particles capable of
reaching the lungs. In a paper by Pavkov the peak inspiratory ﬂow
through Breezhaler was evaluated in 26 moderate to severe COPD
patients, who were able to generate a ﬂow greater than 60 L/min
[21]. Very few data are available regarding lung deposition: it was
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be delivered through Breezhaler [22].
Dewar demonstrated that patients with severe bronchial
obstruction from COPD can generate sufﬁcient peak inspiratory
ﬂow to operate Turbuhaler effectively [23]. Due to the large amount
of small particles and themoderate inbuilt resistance in Turbuhaler,
which opens up the vocal cords during inhalation, Turbuhaler is
associated with higher lung deposition (25e40% of the delivered
dose) compared with pMDIs and other DPIs [12,16]. A good corre-
lation has been found between lung deposition and clinical efﬁcacy.
A high lung deposition always results in the best ratio between
clinical efﬁcacy and risk of unwanted systemic activity [24]. Studies
with Turbuhaler also show that the in vivo variation in lung
deposition is signiﬁcantly lower compared with a pMDI or, for
example, the Diskus inhaler, and much lower than the in vitro dose
variability seen in laboratory tests [18].
However, due to the complex interaction of ﬂow rate, particle
sizes, acceleration rates/disaggregation and inhalation volumes,
many questions remain to be fully answered. Clinical randomized
trials do not reﬂect the population of patients using inhalers. Future
studies that can assess all of these separate parameters in a variety
of patients, in real-life, would provide beneﬁcial insight into this
area. Other parameters, such as the feedback system or the required
steps to activate the device variably affect the effectiveness of the
inhaled treatment in clinical settings. Table 1 summarizes the main
properties for each inhaler.6. Patient adherence in the management of chronic
obstructive respiratory diseases
Patients play amajor role in determining the success or failure of
treatment. “Adherence” must be distinguished from “compliance”,
the difference being in the patient's willingness to accept therapy
[25]: the “non-compliant” patient simply ignores prescriptions.
Adherent patients take medications as prescribed, whereas “non-
adherent” patients fail to do so despite their willingness and
acceptance of therapy. The unwitting non-adherence that occurs
when a patient does not know the proper inhaler technique or does
not understand the difference between a rescue and controller
medication is common in real life. The issue of patient age is
particularly important in unintentional non-adherence. Young
children dependent on others for delivery of medication and are
frequently unable to communicate their perception of symptom
severity. In these patients, the common use of nebulizers makes the
administration of asthmamedication particularly tedious and time-
consuming [26]. However, other factors, including fear of stigma-
tisation at school, fear of side effects, fear of dependence can
signiﬁcantly reduce adherence in school-age children [27]. As
psychological distress is associated with non-adherence, accurate
screening for unhealthy behaviours should be part of a compre-
hensive approach to adolescents with asthma.
In elderly patients, unintentional non-adherence to inhalation
therapy represents a complex problem that may lead to signiﬁcant
impairment of symptom control. Elderly patients often suffer from
cognitive impairments, hearing or visual problems or otherTable 1
Main features for each device.
Inhaler Loaded Feedbacks Dose counter
Breezhaler NO NO NO
Handihaler NO NO NO
Respimat NO NO NO
Diskus YES NO YES
Turbuhaler YES NO YES
Nexthaler YES NO YESphysical disabilities (e.g., arthritis, tremors and poor coordination)
that signiﬁcantly affect their ability to understand and follow
treatment regimens. In addition, elderly patients often have mul-
tiple chronic diseases requiring multiple medications, and treat-
ment complexity is a major risk factor for reduced adherence. As
previously discussed, the availability of a multitude of inhaler de-
vices can be confusing to the patient. Switching between different
inhalers negatively affects care, as inhaler classes and brands differ
in design, and each device has its own unique requirements and
inhalation technique [28].
Patient training is critical for the correct use of inhaler devices
and the effectiveness of therapy. Healthcare providers should not
assume that correct inhaler use is intuitive, or obvious from the
printed instructions provided with the inhaler. Moreover, they
should not rely on verbal communication alone, but rather provide
clear visual “step by step” instructions with pictures and encourage
patients to take notes on the instruction sheet. Unfortunately, both
patients and healthcare providers underestimate the issue of inha-
lation device incompetence. The fault may also occur in healthcare
provider if competence or training skills are less than optimal [29].
Patient education is critical for reducingunwittingnon-adherence,
and thereby increasing the overall effectiveness of inhalation therapy.
Education entails simpliﬁcation, demonstration and repetition, and
should include anunderstandingofwhy thepatientneeds the inhaler,
how the inhaler works, and the steps required to use it correctly. In-
ternationalguidelines recommend that training shouldbeprovidedat
each visit, and that patients should be encouraged to bring all of their
inhalers to each visit and demonstrate their inhalation technique;
however, a consensus is lacking on how to match patient incompe-
tence with criteria for selecting an alternative inhaler device. We
suggest that rather than insisting with training a patient with a spe-
ciﬁc inhaler device, itwould bemore appropriate tomatch the device
with the behaviour and the skills of the patient. The “idealhaler” does
not exist in real life. Instead, healthcare providers should carefully
evaluate which device would ﬁt the needs and ability of the patient.
Importantly, the patient's preference should not be neglected.
7. Conclusions
Meta-analyses and systematic reviews [2,3,30] indicate that all
inhalers can be effective and can achieve a similar therapeutic ef-
fect when patients use the inhalation technique recommended by
the manufacturer, although different doses may be required. These
observations are often documented in randomised controlled trials,
where patients receive more inhaler-technique training and
counselling on the importance of adherence than do patients in
routine clinical practice. Real-life investigations conﬁrm that most
patients make at least one error when using the inhaler, and this
often affects delivery of the drug to the bronchial tree. Thus, the
responsibility for maintaining adherence to treatment is shared by
the patient and the clinician, who must provide adequate training
and monitoring. Clinicians have a plethora of effective devices that
can be applied to speciﬁc patient needs; this should be perceived as
an opportunity rather than a limitation.
Acknowledgements
English language editing and styling assistance was provided by
Edra LSWR, Elsevier, and funded by AstraZeneca.
References
[1] Laube BL, Janssens HM, de Jongh FH, Devadason SG, Dhand R, Diot P, et al.
What the pulmonary specialist should know about the new inhalation ther-
apies. Eur Respir J 2011;37(6):1308e31.
N. Scichilone et al. / Pulmonary Pharmacology & Therapeutics 31 (2015) 63e67 67[2] Dolovich MB, Ahrens RC, Hess DR, Anderson P, Dhand R, Rau JL, et al. Device
selection and outcomes of aerosol therapy: evidence-based guidelines:
American College of Chest Physicians/American College of Asthma, Allergy,
and Immunology. Chest 2005;127(1):335e71.
[3] Rubin BK. Pediatric aerosol therapy: new devices and new drugs. Respir Care
2011 Sep;56(9):1411e21.
[4] Giraud V, Roche N. Misuse of corticosteroid metered-dose inhaler is associated
with decreased asthma stability. Eur Respir J 2002;19(2):246e51.
[5] van der Palen J, Klein JJ, van Herwaarden CL, Zielhuis GA, Seydel ER. Multiple
inhalers confuse asthma patients. Eur Respir J 1999;14(5):1034e7.
[6] Dalby RN, Eicher J, Zierenberg B. Development of respimat soft mist inhaler
and its clinical utility in respiratory disorders. Med Devices Auckl 2011;4:
145e55.
[7] Tarsin WY, Pearson SB, Assi KH, Chrystyn H. Emitted dose estimates from
Seretide Diskus and Symbicort Turbuhaler following inhalation by severe
asthmatics. Int J Pharm 2006;316(1e2):131e7.
[8] Chrystyn H. Anatomy and physiology in delivery: can we deﬁne our targets?
Alergy 1999;54(Suppl. 49):82e7.
[9] Fabbri LM, Nicolini G, Olivieri D, Papi A. Inhaled beclometasone dipropio-
nate/formoterol extra-ﬁne ﬁxed combination in the treatment of asthma:
evidence and future perspectives. Expert Opin Pharmacother 2008;9(3):
479e90.
[10] Hozawa S, Terada M, Hozawa M. Comparison of budesonide/formoterol Tur-
buhaler with ﬂuticasone/salmeterol Diskus for treatment effects on small
airway impairment and airway inﬂammation in patients with asthma. Pulm
Pharmacol Ther 2011;24(5):571e6.
[11] Leach CL, Kuehl PJ, Chand R, Ketai L, Norenberg JP, McDonald JD. Character-
ization of respiratory deposition of ﬂuticasone-salmeterol hydroﬂuoroalkane-
134a and hydroﬂuoroalkane-134a beclomethasone in asthmatic patients. Ann
Allergy Asthma Immunol 2012;108(3):195e200.
[12] Olsson B. Aerosol particle generation from dry powder inhalers: can they
equal pressurized metered dose inhalers? J Aerosol Med 1995;8(Suppl. 3):
S13e8.
[13] Zanen P, Go LT, Lammers JW. Optimal particle size for b2-agonists and anti-
cholinergic aerosols in patients with severe airﬂow obstruction. Thorax
1996;51:977e80.
[14] Usmani O, Biddiscombe MF, Nightingale JA, Underwood SR, Barnes PJ. Effects
of bronchodilator particle size in asthmatic patients using monodisperse
aerosols. J Appl Physiol 2003;95:2106e12.
[15] Thorsson L, Edsb€acker S, K€allen A, L€ofdahl CG. Pharmacokinetics and systemic
activity of ﬂuticasone via Diskus and pMDI, and of budesonide via Turbuhaler.
Br J Clin Pharmacol 2001;52(5):529e38.[16] Thorsson L, Kenyon CJ, Newman SP, Borgstr€om L. Lung deposition of bude-
sonide in asthmatics: a comparison of different formulations. Int J Pharm
1998;168(1):119e27.
[17] Borgstr€om L, Asking L, Thorsson L. Idealhalers or realhalers? A comparison of
Diskus and Turbuhaler. Int J Clin Pract 2005 Dec;59(12):1488e95.
[18] Agertoft L, Pedersen S. Lung deposition and systemic availability of ﬂuticasone
Diskus and budesonide Turbuhaler in children. Am J Respir Crit Care Med
2003;168(7):779e82.
[19] Corradi M, Chrystyn H, Cosio BG, Pirozynski M, Loukides S, Louis R, et al.
NEXThaler, an innovative dry powder inhaler delivering an extraﬁne ﬁxed
combination of beclometasone and formoterol to treat large and small air-
ways in asthma. Expert Opin Drug Deliv 2014 Sep;11(9):1497e506.
[20] Colthorpe P, Voshaar T, Kieckbusch T, Cuoghi E, Jauernig J. Delivery charac-
teristics of a low-resistance dry-powder inhaler used to deliver the long-
acting muscarinic antagonist glycopyrronium. J Drug Assess 2013;2:11e6.
[21] Pavkov R, Mueller S, Fiebich K, Singh D, Stowasser F, Pignatelli G, et al.
Characteristics of a capsule based dry powder inhaler for the delivery of
indacaterol. Curr Med Res Opin 2010 Nov;26(11):2527e33.
[22] Molimard M, D'Andrea P. Once-daily glycopyrronium via the Breezhaler®
device for the treatment of COPD: pharmacological and clinical proﬁle, vol. 5;
2013. p. 503e17.
[23] Dewar MH, Jamieson A, McLean A, Crompton GK. Peak inspiratory ﬂow
through Turbuhaler in chronic obstructive airways disease. Respir Med 1999
May;93(5):342e4.
[24] Borgstrom L, Derom E, Stahl E, Wahlin-Boll E, Pauwels R. The inhalation de-
vice inﬂuences lung deposition and bronchodilating effect of terbutaline. Am J
Respir Crit Care Med 1996;153:1636e40.
[25] Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005 Aug
4;353(5):487e97.
[26] Graves MM, Adams CD, Portnoy JM. Adherence in young children with
asthma. Curr Opin Allergy Clin Immunol 2006;6(2):124e7.
[27] Bender BG, Bender SE. Patient-identiﬁed barriers to asthma treatment
adherence: responses to interviews, focus groups, and questionnaires.
Immunol Allergy Clin N Am 2005;25(1):107e30.
[28] Thomas M, Price D, Chrystyn H, Lloyd A, Williams AE, von Ziegenweidt J.
Inhaled corticosteroids for asthma: impact of practice level device switching
on asthma control. BMC Pulm Med 2009;9:1.
[29] Hanania NA,Wittman R, Kesten S, Chapman KR.Medical personnel's knowledge
of and ability to use inhaling devices. Metered-dose inhalers, spacing chambers,
and breath-actuated dry powder inhalers. Chest 1994;105(1):111e6.
[30] Hess DR. Aerosol delivery devices in the treatment of asthma. Respir Care
2008;53(6):699e723.
